The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment
M Frleta, S Siebert, IB McInnes - Current rheumatology reports, 2014 - Springer
Psoriasis and psoriatic arthritis (PsA) are pathophysiological enigmas among rheumatic
diseases. Substantial clinical advances have been made with new therapy targeting …
diseases. Substantial clinical advances have been made with new therapy targeting …
The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment
M Frleta, S Siebert, IB McInnes - Current Rheumatology Reports, 2014 - eprints.gla.ac.uk
Psoriasis and psoriatic arthritis (PsA) are pathophysiological enigmas among rheumatic
diseases. Substantial clinical advances have been made with new therapy targeting …
diseases. Substantial clinical advances have been made with new therapy targeting …
The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment.
M Frleta, S Siebert, IB McInnes - Current Rheumatology Reports, 2014 - europepmc.org
Psoriasis and psoriatic arthritis (PsA) are pathophysiological enigmas among rheumatic
diseases. Substantial clinical advances have been made with new therapy targeting …
diseases. Substantial clinical advances have been made with new therapy targeting …
The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment
M Frleta, S Siebert, IB McInnes - Current rheumatology …, 2014 - pubmed.ncbi.nlm.nih.gov
Psoriasis and psoriatic arthritis (PsA) are pathophysiological enigmas among rheumatic
diseases. Substantial clinical advances have been made with new therapy targeting …
diseases. Substantial clinical advances have been made with new therapy targeting …
The Interleukin-17 Pathway in Psoriasis and Psoriatic Arthritis: Disease Pathogenesis and Possibilities of Treatment
M Frleta, S Siebert, IB McInnes - Current Rheumatology Reports, 2014 - infona.pl
Psoriasis and psoriatic arthritis (PsA) are pathophysiological enigmas among rheumatic
diseases. Substantial clinical advances have been made with new therapy targeting …
diseases. Substantial clinical advances have been made with new therapy targeting …
The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment.
M Frleta, S Siebert, IB McInnes - Current Rheumatology Reports, 2014 - europepmc.org
Psoriasis and psoriatic arthritis (PsA) are pathophysiological enigmas among rheumatic
diseases. Substantial clinical advances have been made with new therapy targeting …
diseases. Substantial clinical advances have been made with new therapy targeting …
The Interleukin-17 Pathway in Psoriasis and Psoriatic Arthritis: Disease Pathogenesis and Possibilities of Treatment
M Frleta, S Siebert, IB McInnes - Current Rheumatology Reports, 2014 - infona.pl
Psoriasis and psoriatic arthritis (PsA) are pathophysiological enigmas among rheumatic
diseases. Substantial clinical advances have been made with new therapy targeting …
diseases. Substantial clinical advances have been made with new therapy targeting …